Biopharma opportunities and macro challenges: A check-up on the industry

The biopharma industry is excited about anti-obesity drugs, neurology, and AI, but high rates and patent expirations have dampened investor enthusiasm. Where are the biggest opportunities now? Goldman Sachs Research’s Asad Haider, Chris Shibutani, and Salveen Richter discuss on the sidelines of our 45th Annual Global Healthcare Conference.